IL159048A0 - Sustained release formulation - Google Patents
Sustained release formulationInfo
- Publication number
- IL159048A0 IL159048A0 IL15904802A IL15904802A IL159048A0 IL 159048 A0 IL159048 A0 IL 159048A0 IL 15904802 A IL15904802 A IL 15904802A IL 15904802 A IL15904802 A IL 15904802A IL 159048 A0 IL159048 A0 IL 159048A0
- Authority
- IL
- Israel
- Prior art keywords
- sustained release
- release formulation
- formulation
- sustained
- release
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 238000013268 sustained release Methods 0.000 title 1
- 239000012730 sustained-release form Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH] (Somatotropin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30027501P | 2001-06-21 | 2001-06-21 | |
PCT/US2002/019597 WO2003000282A1 (fr) | 2001-06-21 | 2002-06-21 | Formulation a liberation lente |
US10/176,961 US7318931B2 (en) | 2001-06-21 | 2002-06-21 | Sustained release formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
IL159048A0 true IL159048A0 (en) | 2004-05-12 |
Family
ID=26872798
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15904802A IL159048A0 (en) | 2001-06-21 | 2002-06-21 | Sustained release formulation |
Country Status (10)
Country | Link |
---|---|
US (2) | US7318931B2 (fr) |
EP (1) | EP1397155B1 (fr) |
JP (2) | JP4460892B2 (fr) |
AU (1) | AU2002320122B2 (fr) |
CA (1) | CA2448218C (fr) |
DK (1) | DK1397155T3 (fr) |
ES (1) | ES2554106T3 (fr) |
IL (1) | IL159048A0 (fr) |
PT (1) | PT1397155E (fr) |
WO (1) | WO2003000282A1 (fr) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1397155E (pt) * | 2001-06-21 | 2015-12-07 | Genentech Inc | Formulação de libertação sustentada |
US20040001889A1 (en) | 2002-06-25 | 2004-01-01 | Guohua Chen | Short duration depot formulations |
US7160551B2 (en) * | 2002-07-09 | 2007-01-09 | The Board Of Trustees Of The University Of Illinois | Injectable system for controlled drug delivery |
US20040033228A1 (en) * | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
MXPA05002991A (es) * | 2002-09-18 | 2005-10-05 | Univ Montreal Ct Hospitalier Chum | Analogos de ghrh. |
MY150740A (en) * | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
SI2218448T1 (sl) | 2002-12-13 | 2016-01-29 | Durect Corporation | Sistem za oralno dajanje zdravila, ki obsega tekoči nosilec materialov z visoko viskoznostjo |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
DE10312346A1 (de) * | 2003-03-20 | 2004-09-30 | Bayer Healthcare Ag | Kontrolliertes Freisetzungssystem |
KR20060002922A (ko) * | 2003-03-31 | 2006-01-09 | 알자 코포레이션 | 비수성 단일 상 비히클 및 이러한 비히클을 이용한 제형 |
ES2300758T3 (es) | 2003-05-01 | 2008-06-16 | Ltt Bio-Pharma Co., Ltd. | Composicion de liberacion sostenida que contiene cinc, su preparacion y procedimiento para producir la misma. |
JP2007517522A (ja) * | 2004-01-07 | 2007-07-05 | トリメリス,インコーポレーテッド | HIVgp41HR2由来の合成ペプチド、およびヒト免疫不全ウイルスの伝播を阻止する治療におけるその使用 |
US20050266087A1 (en) * | 2004-05-25 | 2005-12-01 | Gunjan Junnarkar | Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium |
KR101351771B1 (ko) | 2004-09-17 | 2014-02-17 | 듀렉트 코퍼레이션 | 바람직하게 saib와 같은 당 에스테르를 포함하는지속적인 국소 마취제 조성물 |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
WO2006083761A2 (fr) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solutions de solvant/polymere utilisees comme vehicules de suspension |
US20070027105A1 (en) | 2005-07-26 | 2007-02-01 | Alza Corporation | Peroxide removal from drug delivery vehicle |
EP1912676A2 (fr) * | 2005-07-28 | 2008-04-23 | (Osi) Eyetech, Inc. | Conjugue de polymere comportant un lieur cyclitol |
DK1989220T3 (da) * | 2006-02-02 | 2012-04-02 | Trimeris Inc | HIV-fusionsinhibitorpeptider med forbedrede biologiske egenskaber |
ES2351527T3 (es) | 2006-05-30 | 2011-02-07 | Intarcia Therapeutics, Inc | Modulador de flujo en dos piezas con conducto interno para un sistema osmótico de administración. |
NZ574524A (en) | 2006-08-09 | 2011-07-29 | Intarcia Therapeutics Inc | Piston assembly for positioning lumen of a reservoir for an osmotic delivery having a columnar body and a spring |
PT2117521E (pt) | 2006-11-03 | 2012-09-10 | Durect Corp | Sistemas de administração transdérmica que compreendem bupivacaína |
AU2007234612B2 (en) | 2006-12-14 | 2013-06-27 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein stabilization formulations |
CN101678125A (zh) * | 2007-04-03 | 2010-03-24 | 特里梅里斯公司 | 用于递送抗病毒肽治疗剂的新制剂 |
EP2157967B1 (fr) | 2007-04-23 | 2013-01-16 | Intarcia Therapeutics, Inc | Formulations en suspension de peptides insulinotropes et leurs utilisations |
US7678764B2 (en) | 2007-06-29 | 2010-03-16 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein formulations for use at elevated temperatures |
JP5323832B2 (ja) | 2007-08-07 | 2013-10-23 | アドバンスト・テクノロジーズ・アンド・リジェネレイティブ・メディスン・エルエルシー | 酸性水溶液中にgdf−5を含むタンパク質製剤 |
JP2010540528A (ja) * | 2007-09-25 | 2010-12-24 | トリメリス,インコーポレーテッド | 治療的抗ウイルス性ペプチドの新規合成方法 |
US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
AU2008347158B8 (en) | 2007-12-06 | 2013-08-22 | Durect Corporation | Oral pharmaceutical dosage forms |
WO2009100216A1 (fr) * | 2008-02-08 | 2009-08-13 | Qps Llc | Composition pour une administration à libération prolongée de protéines ou de peptides |
WO2009102467A2 (fr) | 2008-02-13 | 2009-08-20 | Intarcia Therapeutics, Inc. | Dispositifs, formulations et méthodes d’administration de plusieurs agents bénéfiques |
CA2720845A1 (fr) | 2008-04-14 | 2009-10-22 | Advanced Technologies And Regenerative Medicine, Llc | Formulations liquides tamponnees de gdf-5 |
US20100260844A1 (en) | 2008-11-03 | 2010-10-14 | Scicinski Jan J | Oral pharmaceutical dosage forms |
CN102301235B (zh) * | 2008-11-28 | 2014-11-19 | Abbvie公司 | 稳定的抗体组合物和用于稳定其的方法 |
JP2012526121A (ja) * | 2009-05-04 | 2012-10-25 | アボツト・バイオテクノロジー・リミテツド | ヒト抗tnfアルファ抗体の安定した高蛋白質濃度製剤 |
LT2462246T (lt) | 2009-09-28 | 2017-11-27 | Intarcia Therapeutics, Inc | Esminio stacionaraus vaisto tiekimo greitas įgyvendinimas ir (arba) nutraukimas |
JP2013522239A (ja) * | 2010-03-12 | 2013-06-13 | サーモディクス,インコーポレイテッド | 注射用薬物送達システム |
BR112013003671A2 (pt) | 2010-08-18 | 2017-01-10 | Del Mar Pharmaceuticals | composições e métodos para melhorar os benefícios terapêuticos de compostos químicos administyrados sub-otimamente incluindo hexitóis substituídos tais como dianidrogalactitol e diacetildianidrogalactiol |
MX344727B (es) | 2010-11-11 | 2017-01-05 | Abbvie Biotechnology Ltd | Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas. |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
WO2014081405A2 (fr) | 2011-08-17 | 2014-05-30 | Dennis Brown | Compositions et procédés pour améliorer le bénéfice thérapeutique de composés chimiques administrés de manière suboptimale, notamment des hexitols substitués tels que le dibromodulcitol |
EA037797B1 (ru) | 2011-10-25 | 2021-05-21 | Протена Байосайенсиз Лимитед | Состав антитела, пригодный для профилактики и лечения амилоидоза, его варианты и способ его получения |
CN104427984A (zh) | 2012-01-20 | 2015-03-18 | D·布朗 | 包括二脱水半乳糖醇和类似物的经取代的己糖醇类于治疗包括多形性胶质母细胞瘤和成神经管细胞瘤的肿瘤疾病和癌症干细胞的用途 |
US20150087687A1 (en) | 2012-03-23 | 2015-03-26 | Dennis Brown | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo |
WO2013169600A1 (fr) | 2012-05-09 | 2013-11-14 | Delmar Pharmaceuticals | Utilisation vétérinaire du dianhydrogalactitol, du diacétyldianhydrogalactitol, et du dibromodulcitol pour traiter des malignités |
AU2013280644B2 (en) | 2012-06-26 | 2018-08-02 | Jeffrey A. BACHA | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
EP2983468A4 (fr) | 2013-03-15 | 2016-09-07 | Durect Corp | Compositions ayant un agent de modification rhéologique pour réduire une variabilité de dissolution |
JP2016519684A (ja) | 2013-04-08 | 2016-07-07 | デニス エム ブラウン | 準最適に投与された薬物療法の有効性を改善するための及び/又は副作用を低減するための方法および組成物 |
CN112472699A (zh) | 2013-07-26 | 2021-03-12 | 种族肿瘤学公司 | 改善比生群及衍生物的治疗益处的组合方法 |
WO2015058868A1 (fr) | 2013-10-25 | 2015-04-30 | Pangaea Biotech, S.L. | Compositions et procédés pour le traitement du cancer |
JP6564369B2 (ja) | 2013-12-09 | 2019-08-21 | デュレクト コーポレイション | 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法 |
AR101476A1 (es) | 2014-08-07 | 2016-12-21 | Acerta Pharma Bv | Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk) |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
JP6993235B2 (ja) | 2015-06-03 | 2022-01-13 | インターシア セラピューティクス,インコーポレイティド | インプラントの設置及び撤去システム |
EP3458084B1 (fr) | 2016-05-16 | 2020-04-01 | Intarcia Therapeutics, Inc | Polypeptides sélectifs pour le récepteur du glucagon et méthodes pour leur utilisation |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
KR20190104039A (ko) | 2017-01-03 | 2019-09-05 | 인타르시아 세라퓨틱스 인코포레이티드 | Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법 |
WO2021146215A1 (fr) | 2020-01-13 | 2021-07-22 | Durect Corporation | Systèmes d'administration de médicament à libération prolongée avec impuretés réduites et procédés associés |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1456433A (en) * | 1973-06-25 | 1976-11-24 | Quaker Oats Co | Semi-moist cat food |
US4016273A (en) | 1975-07-16 | 1977-04-05 | American Cyanamid Company | Sustained release forms of certain oxazepines for parenteral administration |
DE2916711A1 (de) | 1979-04-25 | 1980-11-06 | Behringwerke Ag | Blutgerinnungsfaktoren und verfahren zu ihrer herstellung |
US5411951A (en) | 1984-10-04 | 1995-05-02 | Monsanto Company | Prolonged release of biologically active somatotropin |
IL79681A (en) * | 1985-08-12 | 1991-06-10 | Int Minerals & Chem Corp | Transition metal complexes of growth hormones and their prolonged release compositions |
JPS62257990A (ja) | 1986-05-02 | 1987-11-10 | 花王株式会社 | 洗剤用酵素顆粒の製造方法 |
WO1989003671A1 (fr) | 1987-10-29 | 1989-05-05 | Dainippon Pharmaceutical Co., Ltd. | Preparation a liberation entretenue |
US5096885A (en) | 1988-04-15 | 1992-03-17 | Genentech, Inc. | Human growth hormone formulation |
JPH0223866A (ja) | 1988-07-11 | 1990-01-26 | Kikkoman Corp | シュークロースホスホリラーゼの安定化法 |
FR2634121B1 (fr) | 1988-07-13 | 1992-05-07 | Imedex | Procede de preparation de microparticules de collagene et produits obtenus |
US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
US4975271A (en) | 1988-12-19 | 1990-12-04 | Vipont Pharmaceutical, Inc. | Muscosal delivery systems for treatment of periodontal disease |
US5324520A (en) | 1988-12-19 | 1994-06-28 | Vipont Pharmaceutical, Inc. | Intragingival delivery systems for treatment of periodontal disease |
US5114929A (en) | 1989-03-21 | 1992-05-19 | Beecham Group P.L.C. | Pharmaceutical formulation |
US5776963A (en) | 1989-05-19 | 1998-07-07 | Hoechst Marion Roussel, Inc. | 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility |
US5077049A (en) | 1989-07-24 | 1991-12-31 | Vipont Pharmaceutical, Inc. | Biodegradable system for regenerating the periodontium |
US5487897A (en) | 1989-07-24 | 1996-01-30 | Atrix Laboratories, Inc. | Biodegradable implant precursor |
US5324519A (en) | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
SE465950B (sv) | 1989-10-23 | 1991-11-25 | Medinvent Sa | Kombination av ett aggregat partikelformat, kristallint eller frystorkat laekemedel med en pseudoplastisk gel foer beredning av ett injicerbart preparat samt foerfarande foer dess framstaellning |
US5133981A (en) | 1989-11-17 | 1992-07-28 | Atrix Laboratories, Inc. | Purification of benzophenanthridine alkaloids extracts from alkaloid extracts |
ZA918526B (en) | 1990-10-30 | 1992-08-26 | Alza Corp | Drug delivery system and method |
JPH04271785A (ja) | 1991-02-28 | 1992-09-28 | Kao Corp | 酵素固形製剤及びその製造方法 |
US5416071A (en) | 1991-03-12 | 1995-05-16 | Takeda Chemical Industries, Ltd. | Water-soluble composition for sustained-release containing epo and hyaluronic acid |
AU1757092A (en) * | 1991-03-28 | 1992-11-02 | Genentech Inc. | Stable growth hormone metal ion formulations |
US5252338A (en) | 1991-06-27 | 1993-10-12 | Alza Corporation | Therapy delayed |
AU2605592A (en) | 1991-10-15 | 1993-04-22 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
US5711968A (en) | 1994-07-25 | 1998-01-27 | Alkermes Controlled Therapeutics, Inc. | Composition and method for the controlled release of metal cation-stabilized interferon |
US5716644A (en) | 1992-06-11 | 1998-02-10 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
US5242910A (en) | 1992-10-13 | 1993-09-07 | The Procter & Gamble Company | Sustained release compositions for treating periodontal disease |
CA2150803C (fr) * | 1992-12-02 | 2006-01-31 | Henry Auer | Hormone de croissance a liberation controlee qui contient des microspheres |
JP3698721B2 (ja) | 1993-02-23 | 2005-09-21 | ジェネンテク・インコーポレイテッド | 有機溶媒を用いて処理したポリペプチドの賦形剤安定化 |
US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
NZ260909A (en) | 1993-07-05 | 1995-04-27 | Takeda Chemical Industries Ltd | Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution |
US6080429A (en) | 1993-10-25 | 2000-06-27 | Genentech, Inc. | Method for drying microspheres |
JP3125610B2 (ja) | 1993-12-24 | 2001-01-22 | 和光純薬工業株式会社 | L−メチオニン γ−リアーゼの安定化法 |
US5594091A (en) | 1994-02-21 | 1997-01-14 | Takeda Chemical Industries, Ltd. | Matrix for sustained-release preparation |
US5556905A (en) | 1994-03-30 | 1996-09-17 | Reilly Industries, Inc. | Physically-modified degradable thermoplastic compositions |
DE69524398T2 (de) | 1994-04-08 | 2002-07-18 | Atrix Lab Inc | Flüssige mittel zur wirkstoffabgabe |
US5626862A (en) | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
US6004549A (en) | 1994-12-14 | 1999-12-21 | Schering Corporation | Crystalline protein controlled release compositions |
PL184531B1 (pl) | 1995-06-07 | 2002-11-29 | Alkermes Inc | Kompozycja o opóźnionym uwalnianiu ludzkiego hormonu wzrostu do wytwarzania leku do terapii |
US5904935A (en) | 1995-06-07 | 1999-05-18 | Alza Corporation | Peptide/protein suspending formulations |
US5968542A (en) | 1995-06-07 | 1999-10-19 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system as a device |
US5747058A (en) * | 1995-06-07 | 1998-05-05 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system |
EP0831786A2 (fr) | 1995-06-07 | 1998-04-01 | Alkermes Controlled Therapeutics, Inc. | Dispositif de liberation d'un agent biologiquement actif stabilise par rapport a l'agregation |
US6413536B1 (en) | 1995-06-07 | 2002-07-02 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system and medical or surgical device |
EP1006935B1 (fr) | 1995-06-07 | 2005-01-26 | Southern Biosystems, Inc. | Systeme d'administration regulee d'un liquide de haute viscosite |
US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
CA2192773C (fr) | 1995-12-15 | 2008-09-23 | Hiroaki Okada | Obtention d'une preparation a liberation prolongee pour injection |
US5792477A (en) | 1996-05-07 | 1998-08-11 | Alkermes Controlled Therapeutics, Inc. Ii | Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent |
US5932547A (en) | 1996-07-03 | 1999-08-03 | Alza Corporation | Non-aqueous polar aprotic peptide formulations |
US5981489A (en) | 1996-07-18 | 1999-11-09 | Alza Corporation | Non-aqueous protic peptide formulations |
US5851229A (en) | 1996-09-13 | 1998-12-22 | Meadox Medicals, Inc. | Bioresorbable sealants for porous vascular grafts |
DE69730093T2 (de) | 1996-10-31 | 2006-07-20 | Takeda Pharmaceutical Co. Ltd. | Zubereitung mit verzögerter Freisetzung |
AU739469B2 (en) | 1996-12-20 | 2001-10-11 | Alza Corporation | Gel composition and methods |
US6197350B1 (en) | 1996-12-20 | 2001-03-06 | Takeda Chemical Industries, Ltd. | Method of producing a sustained-release preparation |
US6051558A (en) | 1997-05-28 | 2000-04-18 | Southern Biosystems, Inc. | Compositions suitable for controlled release of the hormone GnRH and its analogs |
US6113947A (en) | 1997-06-13 | 2000-09-05 | Genentech, Inc. | Controlled release microencapsulated NGF formulation |
US6191107B1 (en) * | 1997-09-26 | 2001-02-20 | Takeda Chemical Industries, Ltd. | Complex of human growth hormone and zinc |
JPH11158200A (ja) | 1997-09-26 | 1999-06-15 | Takeda Chem Ind Ltd | ヒト成長ホルモン・亜鉛複合体及びその用途 |
US6039977A (en) | 1997-12-09 | 2000-03-21 | Alza Corporation | Pharmaceutical hydrogel formulations, and associated drug delivery devices and methods |
WO1999033491A1 (fr) | 1997-12-26 | 1999-07-08 | Yamanouchi Pharmaceutical Co., Ltd. | Compositions medicinales a liberation prolongee |
DE19813010A1 (de) | 1998-03-25 | 1999-10-14 | Aventis Res & Tech Gmbh & Co | Mikrokapseln mit verzögertem Release |
US6174547B1 (en) | 1999-07-14 | 2001-01-16 | Alza Corporation | Dosage form comprising liquid formulation |
US6143314A (en) | 1998-10-28 | 2000-11-07 | Atrix Laboratories, Inc. | Controlled release liquid delivery compositions with low initial drug burst |
HUP0104756A3 (en) * | 1998-12-23 | 2006-04-28 | Amgen Inc Thousand Oaks | Polyol/oil suspensions for the sustained release of proteins |
ATE248587T1 (de) | 1999-06-14 | 2003-09-15 | Baxter Int | Mikrosphären mit verzögerter wirkstoffabgabe |
WO2000078335A1 (fr) | 1999-06-18 | 2000-12-28 | Southern Biosystems, Inc. | Compositions pour la liberation regulee de l'hormone gnrh et ses analogues |
US6245806B1 (en) * | 1999-08-03 | 2001-06-12 | Merck & Co., Inc. | HIV integrase inhibitors |
US6458387B1 (en) | 1999-10-18 | 2002-10-01 | Epic Therapeutics, Inc. | Sustained release microspheres |
IL152360A0 (en) | 2000-04-19 | 2003-05-29 | Genentech Inc | Sustained release formulations |
US6719992B2 (en) | 2000-06-26 | 2004-04-13 | Monsanto Technology Llc | Non-aqueous surfactant-containing formulations for extended release of somatotropin |
PT1397155E (pt) | 2001-06-21 | 2015-12-07 | Genentech Inc | Formulação de libertação sustentada |
GB2403086B (en) | 2003-06-17 | 2005-07-20 | Motorola Inc | Cartesian loop transmitter and method of adjusting an output level of such transmitter |
EP3173096A1 (fr) * | 2011-04-06 | 2017-05-31 | Biovaxim Limited | Compositions pharmaceutiques pour prévenir et/ou traiter une maladie vih chez l'homme |
-
2002
- 2002-06-21 PT PT2749622T patent/PT1397155E/pt unknown
- 2002-06-21 DK DK02749622.3T patent/DK1397155T3/en active
- 2002-06-21 WO PCT/US2002/019597 patent/WO2003000282A1/fr active IP Right Grant
- 2002-06-21 CA CA2448218A patent/CA2448218C/fr not_active Expired - Lifetime
- 2002-06-21 IL IL15904802A patent/IL159048A0/xx active IP Right Grant
- 2002-06-21 US US10/176,961 patent/US7318931B2/en not_active Expired - Lifetime
- 2002-06-21 AU AU2002320122A patent/AU2002320122B2/en not_active Expired
- 2002-06-21 EP EP02749622.3A patent/EP1397155B1/fr not_active Expired - Lifetime
- 2002-06-21 ES ES02749622.3T patent/ES2554106T3/es not_active Expired - Lifetime
- 2002-06-21 JP JP2003506926A patent/JP4460892B2/ja not_active Expired - Lifetime
-
2007
- 2007-12-12 US US11/954,608 patent/US8067020B2/en not_active Expired - Fee Related
-
2009
- 2009-08-26 JP JP2009195264A patent/JP2010013456A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
PT1397155E (pt) | 2015-12-07 |
CA2448218C (fr) | 2012-05-29 |
CA2448218A1 (fr) | 2003-01-03 |
US7318931B2 (en) | 2008-01-15 |
ES2554106T3 (es) | 2015-12-16 |
EP1397155A1 (fr) | 2004-03-17 |
JP2010013456A (ja) | 2010-01-21 |
US8067020B2 (en) | 2011-11-29 |
JP2005508299A (ja) | 2005-03-31 |
EP1397155B1 (fr) | 2015-09-30 |
DK1397155T3 (en) | 2015-12-07 |
US20030045454A1 (en) | 2003-03-06 |
JP4460892B2 (ja) | 2010-05-12 |
WO2003000282A1 (fr) | 2003-01-03 |
US20080090754A1 (en) | 2008-04-17 |
AU2002320122B2 (en) | 2007-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL159048A0 (en) | Sustained release formulation | |
IL166424A0 (en) | Sustained release formulations comprising lamotigine | |
EP1537880A4 (fr) | Preparation a liberation prolongee | |
EG24074A (en) | Formulation | |
EP1383376A4 (fr) | Formulations pharmaceutiques a liberation prolongee | |
EP1411904A4 (fr) | Composition pharmaceutique a liberation prolongee | |
AU2002337803A1 (en) | Sustained release pharmaceutical compositions | |
EP1372614A4 (fr) | Preparation de sulfonyluree a liberation controlee | |
GB0000891D0 (en) | Formulation | |
GB0207438D0 (en) | Formulation | |
HUP0301177A3 (en) | Ion-strength independent sustained release pharmaceutical formulation | |
GB0205504D0 (en) | Formulation | |
GB0125492D0 (en) | Formulation | |
GB2375048B (en) | Formulation | |
GB2396812B (en) | Formulation | |
GB0122162D0 (en) | Agent | |
GB0106987D0 (en) | Immunotherapeuitic agent | |
GB0116619D0 (en) | Formulation | |
HK1054508A1 (zh) | 新型製劑 | |
GB0115893D0 (en) | Formulations | |
GB0112497D0 (en) | Formulation | |
GB0111389D0 (en) | Controlled release formulations | |
SI1368006T1 (sl) | Nova formulacija z modificiranim sproscanjem | |
GB0107226D0 (en) | Formulations | |
ZA200305944B (en) | Novel modified release formulation. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed |